Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma

BACKGROUND: In this study, compared to sunitinib as one of the available treatment options, we aimed to evaluate the cost-effectiveness of lenvatinib plus pembrolizumab or everolimus as first-line treatment for advanced renal cell carcinoma (RCC) patients in a Chinese health system setting. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ye, Wang, Hao, Yi, Manman, Han, Zhou, Li, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254865/
https://www.ncbi.nlm.nih.gov/pubmed/35800045
http://dx.doi.org/10.3389/fonc.2022.853901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254865/
https://www.ncbi.nlm.nih.gov/pubmed/35800045
http://dx.doi.org/10.3389/fonc.2022.853901

Ejemplares similares